Compare AYTU & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | TXMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 24.4M |
| IPO Year | 2015 | 2012 |
| Metric | AYTU | TXMD |
|---|---|---|
| Price | $2.21 | $2.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 40.3K | 37.0K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $27,632,080.00 | $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $182.00 |
| Revenue Growth | ★ 277.47 | 35.25 |
| 52 Week Low | $1.65 | $0.98 |
| 52 Week High | $3.07 | $2.95 |
| Indicator | AYTU | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | 60.61 |
| Support Level | $2.17 | $2.15 |
| Resistance Level | $2.30 | $2.32 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 41.94 | 93.75 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.